Interestingly, mRNA expression of other genes involved in cancer invasiveness such as DVL3, CTNNB1, MMP7, HER2, AKT1 were not downregulated by shDVL2 alone compared to NTC but reduced in combination of neratinib with shDVL2 compared to NTC + Nert in either or both SKBR3 and BT474 cell lines (p < 0.05) (Fig. 3A-B) indicating promising additive anti-cancer effects of neratinib and DVL2 silencing in HER2+ breast cancer. The gene discussed is DVL3; the disease is breast carcinoma.